Last reviewed · How we verify
NCT03268291
Communicational Program "Trust" to Improve Adherence to Medications
NA trial testing Standard outpatient observation in Coronary Artery Disease in 2,000 participants. Status unknown.
30 December 2019
Quick facts
| Lead sponsor | Meshalkin Research Institute of Pathology of Circulation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 2,000 |
| Start date | 1 March 2017 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Standard outpatient observation
- Communicational program "Trust"
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Myocardial Infarction — all drugs for Myocardial Infarction →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Who can join
18 and older, any sex, with Coronary Artery Disease or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The trial was designed in such a way as to show that the proposed program "Trust" increases the proportion of patients who adhere to therapy in the cohort of those with coronary heart disease for two years after successful revascularization by using thrombolytic or stenting of the coronary arteries against the background of myocardial infarction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03268291
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Meshalkin Research Institute of Pathology of Circulation trials
Trials by the same sponsor.
- NCT07372196 — Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy · NA · recruiting
- NCT06443931 — Cryoablation of Intercostal Nerves for Pain Management in Early Postoperative Period in Patients With Minimally Invasive · NA · completed
- NCT06069115 — Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort · recruiting
- NCT05856461 — Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension · NA · unknown
- NCT05643664 — The Role of Artificial Intelligence in the Treatment of Abdominal Aortic Aneurysms · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03268291 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meshalkin Research Institute of Pathology of Circulation
- Last refreshed: 31 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03268291.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing